CHICAGO, May 17- The Federal Reserve has not done enough to lower U.S. borrowing costs to boost economic growth, a top Fed official said on Friday, citing his outlook for overly low inflation and overly high unemployment over the next two to three years.» Read More
*Trade balance $31.6 bln vs $19.7 bln f'cast, Nov $19.6 bln. BEIJING, Jan 10- China's export growth rebounded more strongly than expected in December from a three-month low, expanding at the fastest rate in seven months, although the outlook for 2013 remains cloudy with U.S. and European demand for Chinese goods still subdued.
BEIJING, Jan 10- China's export growth is set to rebound from a three-month low in December, although the recovery is likely to be feeble as U.S. and European demand for Chinese goods is still far below levels that would herald a convincing revival.
NEW YORK, Jan 9- Gold fell in light trading on Wednesday after the previous session's gain, while palladium rose over 2 percent as improving U.S. auto sales amid a better economic outlook triggered fund buying. Signs of better Asian physical demand from China and India, however, provide underlying support, traders said.
*World shares rise as Alcoa points to solid global demand. LONDON, Jan 9- World shares staged a modest recovery from two days of losses on Wednesday after aluminium giant Alcoa opened the U.S. earnings season with an optimistic outlook for global demand.
WASHINGTON, Jan 9- The U.S. Congress should accept in the next round of deficit-reduction talks that revenue from taxes must be raised further if it expects President Barack Obama to sign off on a deal, the president's top economic adviser, Gene Sperling, said in an interview.
LONDON, Jan 9- Brent crude oil stayed below $112 per barrel on Wednesday, as a slightly more optimistic outlook for the global economy was offset by lingering concerns about Europe and increasing supply from the United States. Front-month Brent futures shed 11 cents to $111.83 per barrel at 0932 GMT, after adding 54 cents on Tuesday.
Jan 8- Alcoa Inc, the largest aluminum producer in the U.S., expressed cautious optimism that demand for the metal will continue to grow in 2013, helped in part by global growth in the aerospace and construction markets.
What to expect in tomorrow's trading session, with Cliff Davis, BNP Paribas; Robert Luna, SureVest Capital Management; and Laif Meidell, American Wealth Management.
CNBC's John Harwood reports the latest on the U.S. debt; and discussing whether the debt ceiling fight will damage the economy, with CNBC's Steve Liesman and Lindsey Piegza, FTN financial economist.
Alcoa CEO Klaus Kleinfeld discusses quarterly earnings, and his expectations for markets and business in 2013.
CNBC's Maria Bartiromo reports Alcoa's Q4 earnings.
The market is closing lower for a second day as earnings season kicks off with Alcoa reporting in a few moments, with Mark Newton, Greywolf Execution Partners; David Sowerby, Loomis Sayles; and Scott Wren, Wells Fargo Advisors.
Alcoa is set to kick off Q4's earnings season, and discussing how important its announcement to the market is, Ben Willis, Albert Fried & Co.
CNBC's Jeff Cox offers insight on a trend he sees in the markets that says there will be more days in the red in the immediate future. Richard Bernstein, Richard Bernstein Advisors CEO, weighs in.
Bob Doll, Nuveen Asset Management, explains why he thinks 2013 will be a winning year for the markets.
Harry Dent of HS Dent Investment Management explains why he predicts a market crash in the third quarter of the year and that the U.S. is headed towards bankruptcy. Ed Butowsky, Chapwood Investments; Carol Roth, author of "The Entrepreneur Equation"; and CNBC's Rick Santelli, weigh in.
CNBC's Sharon Epperson and American Petroleum Institute CEO Jack Gerard discuss plans for the Keystone XL Pipeline.
The iShare Biotech ETF is up 32 percent over the past year. Jean-Jacques Bienaime, BioMarin Pharmaceutical CEO, discusses the reason behind his company behind up 24.9 percent in the last 3 months.
Discussing opportunities in the market, with Andrew Slimmon, Morgan Stanley Wealth Management.
Onyx Pharmaceuticals CEO Dr. Anthony Coles discusses his company's thyroid cancer drug and its blood cancer drug and its partnership with Bayer.